NOVO NORDISK A/S Under the programme initiated 28 October 2016, Novo Nordisk will repurchase B shares for an amount up to DKK 4.5 billion in the period from 28 October 2016 to 31 January 2017.
Since the announcement as of 16 January 2017, the following transactions have been made under the programme:
Number of B shares | Average purchase price | Transaction value, DKK | |
Accumulated, last announcement | 15,409,793 | 3,711,002,927 | |
16 January 2017 | 300,000 | 253.55 | 76,065,411 |
17 January 2017 | 275,000 | 251.37 | 69,127,706 |
18 January 2017 | 242,400 | 250.44 | 60,706,455 |
19 January 2017 | 250,283 | 250.23 | 62,629,521 |
20 January 2017 | 262,734 | 249.37 | 65,517,975 |
Accumulated under the programme | 16,740,210 | 4,045,049,995 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
Page 2 of 2
With the transactions stated above, Novo Nordisk owns a total of 49,839,192 B shares of DKK 0.20, corresponding to 2.0% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,550,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 3 February 2016. As of 20 January 2017, Novo Nordisk has repurchased a total of 47,915,547 B shares equal to a transaction value of DKK 14,544,808,441.
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,300 people in 75 countries and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube
Further informationMedia: | ||
Anne Margrethe Hauge | +45 4442 3450 | amhg@novonordisk.com |
Ken Inchausti (US) | +1 609 786 8316 | kiau@novonordisk.com |
Investors: | ||
Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com |
Melanie Raouzeos | +45 3075 3479 | mrz@novonordisk.com |
Hanna Ögren | +45 3079 8519 | haoe@novonordisk.com |
Anders Mikkelsen | +45 3079 4461 | armk@novonordisk.com |
Kasper Veje (US) | +1 609 235 8567 | kpvj@novonordisk.com |
Novo Nordisk A/S published this content on 23 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 30 January 2017 15:54:19 UTC.
Original documenthttp://www.novonordisk.com/bin/getPDF.2072842.pdf
Public permalinkhttp://www.publicnow.com/view/0999F61B8BB2216265B5A0B46E01817CF87C7DAB
